ArticleFish physiology and biochemistry2025
Exemestane induces liver toxicity in zebrafish larvae by upregulating the p53 signaling pathway.
Article in Fish physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Exemestane is an aromatase inhibitor that is used for the treatment of breast cancer. The aim of this study was to evaluate the effects of exemestane on liver development of zebrafish embryos. In this study, zebrafish embryos at 72 h post-fertilization (hpf) were exposed to varying concentrations (1, 2, and 3 mg/L) of exemestane for 72 h (until 144 hpf). The results demonstrated that exemestane exposure significantly reduced liver area and expanded the yolk sac in a dose-dependent manner, accompanied by progressive lipid accumulation. At the highest concentration (3 mg/L), exemestane markedly downregulated the expression of key liver development markers, including fatty acid-binding protein (fabp10a) and ceruloplasmin (cp). The study further revealed that exemestane exposure at 2 mg/L and 3 mg/L significantly increased reactive oxygen species (ROS) levels while decreasing the activities of antioxidant enzymes, specifically catalase (CAT) and superoxide dismutase (SOD). Interestingly, higher concentrations of exemestane resulted in reduced levels of the lipid peroxidation product malondialdehyde (MDA) and decreased mitochondrial numbers. Additionally, exemestane treatment altered the expression of genes related to sugar and lipid metabolism and upregulated pro-apoptotic genes, including bax, p53, and caspase 3, in zebrafish embryos. A crucial finding was that p53 knockdown in zebrafish embryos effectively mitigated the hepatotoxic effects induced by exemestane. These collective results indicate that exemestane induces hepatotoxicity in zebrafish primarily through activation of the p53 signaling pathway. This study provides valuable insights into the potential hepatotoxic effects of exemestane, offering important references for its clinical safety evaluation.
Indexed as
Identifiers
41114735What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.